Trial Profile

A Phase Ib/II Trial of Siltuximab and Spartalizumab in Metastatic Pancreatic Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Siltuximab (Primary) ; Spartalizumab (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions

Most Recent Events

10 Apr 2024 Results assessing safety and efficacy of of siltuximab and spartalizumab in advanced pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research
22 Sep 2023 Status changed from active, no longer recruiting to completed.
13 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com